<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>CENTUSSIN DHC - dihydrocodeine bitartrate, brompheniramine maleate and phenylephrine hydrochloride liquid </strong><br>Centurion Labs, LLC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>CENTUSSIN DHC LIQUID</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>CENTUSSIN DHC Liquid</h1>NDC 23359-018-16<br><span class="Bold">Rx Only</span><br><br><span class="Bold">CV</span><br><br><span class="Bold">DESCRIPTION:</span><br>Each 5 mL (one teaspoonful) for oral administration contains:<br>Dihydrocodeine Bitartrate*........................ 3 mg<br>*(WARNING- May be habit forming)<br>Brompheniramine Maleate........................ 4 mg<br>Phenylephrine Hydrochloride................... 7.5 mg<br><br>CENTUSSIN DHC Liquid also contains: Glycerin, Propylene Glycol, Sorbitol, Citric Acid, Sodium Citrate, <br>Sodium Saccharin, Grape Flavor, Purified Water.<br><br>Dihydrocodeine Bitartrate is an antitussive with the chemical name (Morphinan-6-ol,4,5-epoxy-3-methoxy-<br>17-methyl-, (5α, 6α)-2,3-dihydroxybutanedioate (1:1) (salt). It has the following structural formula:<br><br><div class="Figure"><img alt="Dihydrocodeine Bitartrate Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=315a70bc-bfd8-471d-9379-d2746823537d&amp;name=MM4.jpg"></div>
<br><br>Brompheniramine Maleate is an antihistamine having the chemical name, 2-Pyridinepropanamine, <br>γ-(4-bromophenyl)-N, N-dimethyl-, (±)-,(Z)-2-butenedioate (1:1). With the following structure:<br><br><div class="Figure"><img alt="Brompheniramine Maleate Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=315a70bc-bfd8-471d-9379-d2746823537d&amp;name=MM5.jpg"></div>
<br>Phenylephrine hydrochloride is an orally effective nasal decongestant. Chemically it is (-)-m-Hydroxy-α-<br>[(methylamino)methyl]benzyl alcohol hydrochloride. Its chemical structure is as follows:<br><br><div class="Figure"><img alt="Phenylephrine Hydrochloride Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=315a70bc-bfd8-471d-9379-d2746823537d&amp;name=MM6.jpg"></div>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>Dihydrocodeine is a semi-synthetic narcotic analgesic related to codeine, with multiple actions <br>qualitatively similar to those of codeine; the most prominent of these involve the central nervous <br>system and organs with smooth muscle components. Brompheniramine maleate is an alkylamine <br>type antihistamine. This group of antihistamines is among the most active histamine antagonists <br>and is generally effective in relatively low doses. The drugs are not so prone to produce <br><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and are among the most suitable agents for daytime use, but a significant proportion <br>of patients do experience this effect. Phenylephrine HCl is a sympathomimetic, which acts <br>predominately on alpha-receptors and has little action on beta-receptors. It therefore functions <br>as an oral nasal decongestant with minimal CNS stimulation.<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>CENTUSSIN DHC Liquid is indicated to control <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and provide for temporary relief from <br>congestion associated with the upper respiratory tract.<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>This combination product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to dihydrocodeine, codeine, <br>or any of the active and inactive components listed above, or in any situation where opioids are <br>contraindicated including significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (in unmonitored settings or in the absence <br>of resuscitation equipment), acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, and <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. <br>Antihistamines and sympathomimetics are contraindicated in patients receiving antihypertensive or <br>antidepressant drugs containing monoamine oxidase (MAO) inhibitors. Antihistamines should not be <br>used to treat lower respiratory tract symptoms or be given to premature or newborn infants. <br>Sympathomimetic agents are contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, severe coronary <br>artery disease, patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <br>and during an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack. This product is contraindicated in women who are pregnant.<br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<span class="Bold">General:</span> Considerable caution should be exercised in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <br><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>. <br>The elderly (60 years and older) are more likely to exhibit adverse reactions. Antihistamines may <br>cause <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, especially in children. At dosages higher than the recommended dose, <br><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleeplessness</span> may occur.<br><br><span class="Bold">Usage in Ambulatory Patients:</span> Dihydrocodeine may impair the mental and/or physical abilities <br>required for the performance of potentially hazardous tasks such as driving a car or operating <br>machinery.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>:</span> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the most dangerous acute reaction produced by <br>opioid agonist preparations, although it is rarely severe with usual doses. Opioids decrease the <br><span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, tidal volume, minute ventilation, and sensitivity to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>. Respiratory <br><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> occurs most frequently in elderly more debilitated patients, usually after large initial doses <br>in non-tolerant patients, or when opioids are given in conjunction with other agents that depress <br>respiration. This combination product should be used with caution in patients with significant chronic <br>obstructive pulmonary disease or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span> and in patients with a substantially decreased <br>respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.<br><span class="Bold"><br>Hypotensive Effect:</span> Dihydrocodeine, like all opioid analgesics, may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in patients <br>whose ability to maintain blood pressure has been compromised by a depleted blood volume or who <br>receive concurrent therapy with drugs such as phenothiazines or other agents which compromise <br>vasomotor tone. CENTUSSIN DHC Liquid may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory <br>patients. This combination product should be administered with caution to patients in circulatory <br><span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure.<br><span class="Bold"><br><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</span> Dihydrocodeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the codeine type and has the potential <br>of being abused. This product should be prescribed and administered with the appropriate degree of <br>caution. (See Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> section).<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Bold">General:</span> This combination product should be used with caution in elderly or debilitated patients or <br>those with any of the following conditions: adrenocortical insufficiency (e.g., Addison's disease); <br><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>; <br>decreased respiratory reserve (including <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, severe <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, or <br>kyphoscoliosis); <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>; <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>; <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; increased <br>intracranial pressure; <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>; <br>and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. The benefits and risks of opioids in patients taking monoamine oxidase <br>inhibitors and in those with a history of drug abuse should be carefully considered. This <br>combination product may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and, like <br>all opioids, may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.<br>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<span class="Bold">General: </span>Sympathomimetics may reduce the antihypertensive effects of methyldopa, <br>mecamylamine, reserpine and veratrum alkaloids.<br><br><span class="Bold">Other Central Nervous System Depressants:</span> Patients receiving other opioid analgesics, <br>sedatives or hypnotics, muscle relaxants, general anesthetics, centrally acting anti-emetics, <br>phenothiazines or other tranquilizers, or alcohol concomitantly with this combination product may <br>exhibit additive depressant effects on the central nervous system. When such combined therapy <br>is contemplated, the dose of one or both agents should be reduced. Concomitant use of <br>dihydrocodeine and antihistamines with alcohol and other CNS depressants may have an additive effect.<br><br><span class="Bold">Monoamine Oxidase Inhibitors:</span> Dihydrocodeine, like all opioids, interact with monoamine oxidase <br>inhibitors causing central nervous system excitation and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. MAO inhibitors and <br>beta-adrenergic blockers increase the effects of sympathomimetics. They may also prolong and <br>intensify the anticholinergic effects of antihistamines.<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8"></a><p></p>
<h1>Information for Patient/Caregivers:</h1>Patients receiving CENTUSSIN DHC Liquid should be given the following information:<br>1. Patients should be advised that CENTUSSIN DHC Liquid may impair the mental or physical <br>    abilities required for the performance of potentialy hazardous tasks such as driving a car or <br>    operating machinery.<br>2. Patients should be advised to report adverse experiences occurring during therapy.<br>3. Patients should be advised not to adjust the dose of CENTUSSIN DHC Liquid without <br>    consulting the prescribing professional.<br>4. Patients should not combine CENTUSSIN DHC Liquid with alcohol or other central nervous <br>    system stimulants.<br>5. Women of childbearing potential who become, or are planning to become pregnant should be <br>    advised to consult their physician regarding the effects of opioids and other drug use during <br>    pregnancy on themselves and their unborn child.<br>Patients should be advised that CENTUSSIN DHC Liquid is a potential drug of abuse. They should <br>protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom it <br>was prescribed.<br>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-9"></a><p></p>
<h1>Pregnancy: Teratogenic Effects - Pregnancy Category C:</h1>Animal reproduction studies have not been conducted with CENTUSSIN DHC Liquid. It is also not <br>known whether this combination product can cause fetal harm when administered to pregnant <br>women or can affect reproduction capactiy in males and females. This combination product should <br>be given to pregnant women only if clearly needed, especially during the first trimester.<br><br><span class="Bold">Nonteratogenic Effects:</span> Babies born to mothers who have been taking opioids regularly prior to <br>delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <br><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of <br>maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. <br>Chlorpromazine 0.7-1.0 mg/kg q6h, phenobarbital 2 mg/kg q6h, and paregoric 24 drops/kg q4h, <br>have been used to treat withdrawal symptoms in infants. The duration of therapy is 4 to 28 days, <br>with the dosages decreased as tolerated.<br>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-10"></a><p></p>
<h1>Labor and Delivery:</h1>CENTUSSIN DHC Liquid is not recommended for use by women during and immediately before <br>labor and delivery because oral opioids may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn.<br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-11"></a><p></p>
<h1>Pediatric Use:</h1>This product is not recommended for use in children under 6 years of age. Children under two years <br>may be more susceptible to the <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use of antihistamines is not <br>recommended in infants. This age group may be at a higher risk than other age groups because of <br>an increased susceptibility to anticholinergic effects, such as CNS excitation, and an increased <br>tendency toward <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. In older children taking antihistamines, a paradoxical reaction <br>characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> may occur. Very young children may be more sensitive to the <br>effects, especially the vasopressor effects of sympathomimetic amines.<br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-12"></a><p></p>
<h1>Geriatric Use:</h1>CENTUSSIN DHC Liquid should be given with caution to the elderly.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> CENTUSSIN DHC Liquid should be given with caution to patients with <br><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Since, dihydrocodeine is metabolized by the liver; the effects of this <br>combination product should be monitored closely in such patients.<br><span class="Bold"><br><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> CENTUSSIN DHC Liquid should be used with caution and at reduced dosage <br>in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.<br><span class="Bold"><br>Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span>:</span> Opioids may cause <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the sphincter of Oddi and <br>should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span> including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.<br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-13"></a><p></p>
<h1>ADVERSE REACTIONS</h1>The most frequently observed adverse reactions with dihydrocodeine include light-headedness, <br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, sedation, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <br>pruritis, and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. With the exception of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, tolerance develops to most of <br>these effects. Other reactions that have been observed with dihydrocodeine or other opioids <br>include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4009383" conceptname="Cough suppression">cough suppression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <br><span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, spasm of biliary tract, and urinary <br>retention. Physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> are possibilities. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> <br>(including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>), <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span>, granulomatous interstitial <br><span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, severe <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">narcosis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported rarely during dihydrocodeine <br>administration. Other adverse reactions observed with the ingredients in CENTUSSIN DHC Liquid <br>include, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, dryness of mouth, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, cardiac <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <br><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, increase <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> (especially in children).<br>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-14"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>This combination product is subject to the provisions of the Controlled Substances Act and has <br>been placed in Schedule V. Dihydrocodeine can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the codeine type <br>and therefore has the potential of being abused. Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <br>and tolerance may develop upon repeated administration of dihydrocodeine, and it should be <br>prescribed and administered with the same degree of caution appropriate to the use of other oral <br>opioid medications. Symptoms of dihydrocodeine withdrawal consist of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <br><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.<br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-15"></a><p></p>
<h1>OVERDOSAGE</h1>An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of CENTUSSIN DHC Liquid is a potentially lethal poly-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation, and <br>consultation with a regional Poison Control Center is recommended. A listing of the poison control <br>centers can be found in standard references such as the Physician's Desk Reference.<br><br><span class="Bold">Signs and Symptoms:</span> Symptoms of overdosage include pinpoint pupils, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <br>extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <br><span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin and other symptoms common with narcotic overdosage. <br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. A single case of acute <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> <br>associated with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of dihydrocodeine has been reported.<br><br><span class="Bold">Recommended Treatment:</span> Immediate treatment of an overdosage of CENTUSSIN DHC Liquid <br>includes support of cardiorespiratory function and measures to reduce drug absorption. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> <br>should be induced with syrup of ipecac, if the patient is alert and has adequate laryngeal reflexes. <br>Oral activated charcoal should follow. The first dose should be accompanied by an appropriate <br>cathartic. Gastric lavage may be necessary. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is usually hypovolemic and should be <br>treated with fluids. Endotracheal intubation and artificial respiration may be necessary. The pure <br>opioid antagonist naloxone or nalmefene is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> that <br>results from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Opioid antagonists should not be given in the absence of clinically <br>significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. They should be <br>administered cautiously to persons who are known, or suspected to be, physically dependent on <br>any opioid agonist including dihydrocodeine. In such cases, an abrupt or complete reversal of <br>opioid effects may precipitate an acute abstinence syndrome. The prescribing information for the <br>specific opioid antagonist should be consulted for details of their proper use.<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-16"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION*</h1>
<span class="Bold">Adults and Children 12 years of age or older:</span><br>1 teaspoonful every 4 to 6 hours. Not to exceed 6 teaspoonfuls in a 24 hour period.<br><span class="Bold">Children 6 to 12 years of age:</span> 1/2 teaspoonful every 4 to 6 hours. Not to exceed <br>3 teaspoonfuls in a 24 hour period.<br><span class="Bold">Not recommended for children under 6 years of age.<br><br></span>*In mild cases or in particularly sensitive patients, less frequent or reduced doses may be <br>appropriate and adequate.<br><br><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-17"></a><p></p>
<h1>HOW SUPPLIED</h1>A clear colored liquid with a grape flavor supplied in 16 oz. bottles (NDC 23359-018-16).<br><br><span class="Bold">KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. </span><br><span class="Bold">IN CASE OF ACCIDENTAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span>, SEEK PROFESSIONAL ASSISTANCE </span><br><span class="Bold">OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.</span><br><br>Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.<br><br>This bottle is not to be dispensed to consumer.<br>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-18"></a><p></p>
<h1>Storage:</h1>Store at 15<span class="Sup">o</span>-30<span class="Sup">o</span>C (59<span class="Sup">o</span>-86<span class="Sup">o</span>F). [See USP Controlled Room Temperature.]<br><br>Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.<br><span class="Bold"><br>Rx Only</span><br><br>Manufactured for:<br>Centurion Labs, LLC<br>Birmingham, AL 35236<br><br>Rev. 11/09<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRODUCT PACKAGING:</h1>The packaging below represents the labeling currently used:<br><br><span class="Bold">NDC 23359-018-16</span><br><br><span class="Bold">CENTUSSIN DHC LIQUID</span><br><br>ANTITUSSIVE<br>ANTIHISTAMINE<br>DECONGESTANT<br><br>EACH TEASPOONFUL (5 mL) CONTAINS:<br>Dihydrocodeine Bitartrate*........ 3 mg<br>*(WARNING-May be habit forming)<br>Brompheniramine Maleate....... 4 mg<br>Phenylephrine HCl................ 7.5 mg<br><br>Grape Flavor<br><br><span class="Bold">CV</span><br><br>16 fl oz. (473 mL)<br><br><span class="Bold">Rx Only<br><br></span><br><span class="Bold">Side Panel:</span><br><br><span class="Bold">DOSAGE AND ADMINISTRATION*:</span><span class="Bold">Adults and Children 12 years of age and older:</span><br>1 teaspoonful every 4 to 6 hours. Not to exceed 6 teaspoonfuls in a 24 hour period. <span class="Bold"><br>Children 6 to 12 years of age:</span> 1/2 teaspoonful every 4 to 6 hours. Not to exceed 3 teaspoonfuls <br>in a 24 hour period. <span class="Bold">Not recommended for children under 6 years of age.<br></span><br>*In mild cases or in particularly sensitive patients, less frequent or reduced doses may be appropriate and adequate.<br><br>Refer to the attached package insert for full prescribing information.<br><br><span class="Bold">KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. </span><br><span class="Bold">IN CASE OF ACCIDENTAL <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span>, SEEK PROFESSIONAL ASSISTANCE </span><br><span class="Bold">OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.</span><br><br>Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.<br><br>This bottle is not to be dispensed to consumer.<br><br>Store at 15<span class="Sup">o</span>-30<span class="Sup">o</span>C (59<span class="Sup">o</span>-86<span class="Sup">o</span>F). [See USP Controlled Room Temperature.]<br><span class="Bold"><br>Rx Only</span><br><br>Rev. 11/09<br><br>Manufactured for:<br>CENTURION LABS, LLC<br>LEADING PHARMACEUTICALS<br>Birmingham, AL 35236<br><br><div class="Figure"><img alt="Centussin DHC Liquid" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=315a70bc-bfd8-471d-9379-d2746823537d&amp;name=MM1.jpg"></div>
<br><div class="Figure"><img alt="Centussin DHC Liquid" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=315a70bc-bfd8-471d-9379-d2746823537d&amp;name=MM2.jpg"></div>
<br><div class="Figure"><img alt="Centussin DHC Liquid" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=315a70bc-bfd8-471d-9379-d2746823537d&amp;name=MM3.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CENTUSSIN DHC 		
					</strong><br><span class="contentTableReg">dihydrocodeine bitartrate, brompheniramine maleate, and phenylephrine hydrochloride liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23359-018</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dihydrocodeine Bitartrate</strong> (Dihydrocodeine) </td>
<td class="formItem">Dihydrocodeine Bitartrate</td>
<td class="formItem">3 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Brompheniramine Maleate</strong> (Brompheniramine) </td>
<td class="formItem">Brompheniramine Maleate</td>
<td class="formItem">4 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Phenylephrine Hydrochloride</strong> (Phenylephrine) </td>
<td class="formItem">Phenylephrine Hydrochloride</td>
<td class="formItem">7.5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">GRAPE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23359-018-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">11/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Centurion Labs, LLC
							(806756461)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5912f335-4d16-43c6-b98f-f6aaa9da5877</div>
<div>Set id: 315a70bc-bfd8-471d-9379-d2746823537d</div>
<div>Version: 1</div>
<div>Effective Time: 20091202</div>
</div>
</div> <div class="DistributorName">Centurion Labs, LLC</div></p>
</body></html>
